MISSISSAUGA, ON, Aug. 8, 2012 /PRNewswire/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced medical technologies
company, today announced that it is presenting its latest breakthrough
antimicrobial products, including the recently United States FDA
cleared IV Clear at the 2012 FIME International Medical Expo ("FIME")
from August 8 to 10 in Miami Beach, Florida.
As a seminar guest speaker, Dr. Val DiTizio, Covalon's Chief Scientific
Officer will be discussing why IV Clear is being evaluated by medical
institutions that have adopted programs focused on reducing the
instances of catheter related bloodstream infections. Clinicians have
identified patients who have weak immune systems, sensitive or
compromised skin, or who have long-term catheters as groups who can
benefit the most from IV Clear. Dr. DiTizio's seminar entitled "A
Novel Antimicrobial Clear IV Dressing with Chlorhexidine and Silver"
will be presented at 10:00am in room D238 during the FIME Medical
Educational Conference on Thursday August 9th at the Miami Beach
Covalon will also be showcasing its latest wound care products such as
ColActive® Plus Ag, which is cleared for use in the management of
diabetic ulcers and other chronic wounds and SurgiClear, its unique
antimicrobial transparent silicone adhesive surgical dressing to the
thousands of international and domestic distributors, group purchasing
organizations, hospitals and medical products dealers attending FIME
who are looking for advanced products to license and distribute.
"IV Clear is truly a new innovation in the fight against Catheter
Related Blood Stream Infections ("CRBSI") and we fully expect IV Clear
to be a strong competitor in the United States and International
markets," stated Brian Pedlar, Covalon's Chief Executive Officer. "We
are looking forward to establishing new distribution relationships at
FIME with distributors and hospital buying groups that are interested
in sourcing and licensing IV Clear and other Covalon products."
FIME International Medical Expo, is the largest international medical
trade fair and congress in the United States for conventional medical
distributor networks, group purchasing organizations, integrated
delivery networks, hospitals, imaging centers, private practice
facilities, and home and durable medical equipment providers seeking
the latest medical products from all over the world.
To learn more about Covalon's products and services, please visit
Covalon at booth #365 in the Miami Beach Convention Center in Miami
Beach, Florida from August 8 to 10, 2012 or contact Covalon directly:
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.